Source: http://www.sos.state.tx.us/texreg/archive/March102017/Proposed%20Rules/22.EXAMINING%20BOARDS.html
Timestamp: 2017-09-24 19:12:47
Document Index: 479515629

Matched Legal Cases: ['§137', '§1001', '§137', '§139', '§1001', '§139', '§139', '§139', '§281', '§281', '§281', '§551', '§551', '§554', '§565', '§568', '§281', '§565', '§568', '§281', '§281', '§551', '§554', '§551', '§554', '§281', '§551', '§481', '§291', '§281', '§291', '§291', '§481', '§291', '§291', '§291', '§562', '§551', '§551', '§554', '§291', '§291', '§291', '§291', '§291', '§291', '§291', '§291', '§562', '§291', '§291', '§291', '§291', '§2054', '§562', '§291', '§291', '§291', '§551', '§562', '§315', '§315', '§315', '§481', '§481', 'art 1311']

The Texas Board of Professional Engineers (Board) proposes to repeal §137.19, concerning Engineers Qualified to be Texas Windstorm Inspectors.
The proposed repeal removes rule language that is no longer in effect. This change implements the requirements of House Bill 2439 passed by the 84th Texas Legislature in 2015, which removed the special roster of engineers qualified to be windstorm inspectors.
David Howell, P.E., Deputy Executive Director for the Board, has determined that for the first five-year period the proposed repeal is in effect, there is no adverse fiscal impact for the state and local government as a result of enforcing or administering the section as repealed. There is no additional cost to licensees or other individuals. There is no adverse fiscal impact to the estimated 1,000 small or 6,400 micro businesses regulated by the Board. A Regulatory Flexibility Analysis is not needed because there is no adverse economic effect to small or micro businesses.
Mr. Howell also has determined that for the first five years the proposed repeal is in effect, the public benefit anticipated as a result of enforcing the proposed repeal is an improvement in the flexibility of the licensure processes and the ability to issue international temporary licenses to qualified engineers.
Any comments or request for a public hearing may be submitted no later than 30 days after the publication of this notice to David Howell, P.E., Deputy Executive Director, Texas Board of Professional Engineers, 1917 S. Interstate 35, Austin, Texas 78741, faxed to his attention at (512) 440-0417 or sent by email to rules@engineers.texas.gov.
The repeal is proposed pursuant to the Texas Engineering Practice Act, Occupations Code §1001.202, which authorizes the Board to make and enforce all rules and regulations and bylaws consistent with the Act as necessary for the performance of its duties, the governance of its own proceedings, and the regulation of the practice of engineering in this state.
No other statutes, articles or codes are affected by the proposed repeal.
§137.19.Engineers Qualified to be Texas Windstorm Inspectors.
Filed with the Office of the Secretary of State on February 23, 2017.
TRD-201700740
Earliest possible date of adoption: April 9, 2017
The Texas Board of Professional Engineers (Board) proposes an amendment to §139.35, concerning Sanctions and Penalties.
The proposed amendment removes rule language that is no longer in effect. This change implements the requirements of House Bill 2439 passed by the 84th Texas legislature in 2015, which removed the special roster of engineers qualified to be windstorm inspectors.
David Howell, P.E., Deputy Executive Director for the Board, has determined that for the first five-year period the proposed amendment is in effect, there is no adverse fiscal impact for the state and local government as a result of enforcing or administering the section as amended. There is no additional cost to licensees or other individuals. There is no adverse fiscal impact to the estimated 1,000 small or 6,400 micro businesses regulated by the Board. A Regulatory Flexibility Analysis is not needed because there is no adverse economic effect to small or micro businesses.
Mr. Howell also has determined that for the first five years the proposed amendment is in effect, the public benefit anticipated as a result of enforcing the proposed amendment is an improvement in the flexibility of the licensure processes and the ability to issue international temporary licenses to qualified engineers.
The amendment is proposed pursuant to the Texas Engineering Practice Act, Occupations Code §1001.202, which authorizes the Board to make and enforce all rules and regulations and bylaws consistent with the Act as necessary for the performance of its duties, the governance of its own proceedings, and the regulation of the practice of engineering in this state.
No other statutes, articles or codes are affected by the proposed amendment.
§139.35.Sanctions and Penalties.
(b) The following is a table of suggested sanctions the board may impose against license holders for specific violations of the Act or board rules. NOTE: In consideration of subsection (a)(1) - (6) of this section, the sanction issued could be less than or greater than the suggested sanctions shown in the following table. Also, for those suggested sanctions that list "suspension", all or any portion of the sanction could be probated depending on the severity of each violation and the specific case evidence.
Figure: 22 TAC §139.35(b) (.pdf)
[Figure: 22 TAC §139.35(b)]
(c) - (e) (No change.)
TRD-201700741
Lance Kinney, P. E.
SUBCHAPTER C. DISCIPLINARY GUIDELINES
22 TAC §281.61
The Texas State Board of Pharmacy proposes amendments to §281.61, concerning Definitions of Discipline Authorized. The amendments to §281.61, if adopted, update the definition of probation and revocation.
Gay Dodson, R.Ph., Executive Director/Secretary, has determined that, for the first five-year period the rule is in effect, there will be no fiscal implications for state or local government as a result of enforcing or administering the rule.
Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the amendments will ensure licensees are appropriately disciplined. There is no fiscal impact for individuals, small or large businesses, or to other entities which are required to comply with this section.
Written comments on the amendments may be submitted to Allison Vordenbaumen Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas, 78701, FAX (512) 305-6778. Comments must be received by 5:00 p.m., April 14, 2017.
The amendments are proposed under §§551.002, 554.051, 565.051, and 568.0035 of the Texas Pharmacy Act (Chapters 551 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act. The Board interprets §565.051 and §568.0035 as authorizing the agency to discipline a license or registration.
§281.61.Definitions of Discipline Authorized.
For the purpose of the Act, §565.051 and §568.0035:
(1) "Probation" means a period of supervision by the board [the suspension of a sanction] imposed against a license or registration [during good behavior,] for a term and under conditions as determined by the board, including a probation fee.
(2) "Reprimand" means a public and formal censure against a license or registration.
(3) "Restrict" means to limit, confine, abridge, narrow, or restrain a license or registration for a term and under conditions determined by the board.
(4) "Revoke" means a license or registration is void and may not be reissued; provided, however, upon the expiration of 12 months from and after the effective date of the order revoking a license or registration, the license or registration may be reinstated by [application may be made to] the board [by the former licensee or registrant for the issuance of a license or registration] upon the successful completion of any requirements determined by the board.
(5) "Suspend" means a license or registration is of no further force and effect for a period of time as determined by the board.
(6) "Retire" means a license or registration has been withdrawn and is of no further force and effect.
Filed with the Office of the Secretary of State on February 27, 2017.
TRD-201700762
For further information, please call: (512) 305-8028
22 TAC §281.65
The Texas State Board of Pharmacy proposes amendments to §281.65, concerning Schedule of Administrative Penalties. The amendments, if adopted, will add an administrative penalty for operating a Class E or Class E - S pharmacy without a Texas licensed pharmacist and accessing information submitted to the Prescription Monitoring Program.
Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the amendments will ensure appropriate administrative penalties for violations of the laws and rules governing the practice of pharmacy. There is no fiscal impact for individuals, small or large businesses, or to other entities which are required to comply with this section.
The amendments are proposed under §551.002 and §554.051 of the Texas Pharmacy Act (Chapters 551 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act.
§281.65.Schedule of Administrative Penalties.
The board has determined that the assessment of an administrative penalty promotes the intent of §551.002 of the Act. In disciplinary matters, the board may assess an administrative penalty in addition to any other disciplinary action in the circumstances and amounts as follows:
(1) The following violations by a pharmacist may be appropriate for disposition with an administrative penalty with or without additional sanctions or restrictions:
(A) - (DD) (No change.)
(EE) accessing information submitted to the Prescription Monitoring Program in violation of §481.076 of the Controlled Substances Act: $1,000 - $5,000.
(2) The following violations by a pharmacy may be appropriate for disposition with an administrative penalty with or without additional sanctions or restrictions:
(A) failing to provide patient counseling: $1,500;
(B) failing to conduct a drug regimen review or inappropriate drug regimen reviews provided by §291.33(c)(2)(A) of this title (relating to Operational Standards): $1,500;
(C) failing to clarify a prescription with the prescriber: $1,500;
(D) failing to properly supervise or improperly delegating a duty to a pharmacy technician: $1,500;
(E) failing to identify the dispensing pharmacist on required pharmacy records: $500;
(F) failing to maintain records of prescriptions: $500;
(G) failing to provide or providing false or fraudulent information on any application, notification, or other document required under this Act, the Dangerous Drug Act, or Controlled Substances Act, or rules adopted pursuant to those Acts: $1,000;
(H) following an accountability audit, shortages of prescription drugs: up to $5,000;
(I) dispensing a prescription drug pursuant to a forged, altered, or fraudulent prescription: up to $5,000;
(J) dispensing unauthorized prescriptions: up to $5,000;
(K) dispensing controlled substances or dangerous drugs to an individual or individuals in quantities, dosages, or for periods of time which grossly exceed standards of practice, approved labeling of the federal Food and Drug Administration, or the guidelines published in professional literature: up to $5,000;
(L) violating a disciplinary order of the Board: $1,000 - $5,000;
(M) failing to report or to assure the report of a malpractice claim: up to $1,000;
(N) failing to respond within the time specified on a warning notice to such warning notice issued as a result of a compliance inspection or responding to a warning notice as a result of a compliance inspection in a manner that is false or misleading: up to $1,000;
(O) allowing a pharmacist to practicing pharmacy with a delinquent license: $250 - $1,000;
(P) operating a pharmacy with a delinquent license: $1,000 - $5,000;
(Q) allowing an individual to perform the duties of a pharmacy technician without a valid registration: $500 - $3,000;
(R) failing to comply with the requirements of the Official Prescription Program: up to $1,000;
(S) aiding and abetting the unlicensed practice of pharmacy, if an employee of the pharmacy knew or reasonably should have known that the person engaging in the practice of pharmacy was unlicensed at the time: up to $5,000;
(T) receiving a conviction or deferred adjudication for a misdemeanor or felony which serves as a ground for discipline under the Act: up to $5,000;
(U) unauthorized substitutions: $1,000;
(V) submitting false or fraudulent claims to third parties for reimbursement of pharmacy services: up to $5,000;
(W) possessing or engaging in the sale, purchase, or trade or the offer to sell, purchase, or trade of misbranded prescription drugs or prescription drugs beyond the manufacturer's expiration date: up to $1,000;
(X) possessing or engaging in the sale, purchase, or trade or the offer to sell, purchase, or trade of prescription drug samples as provided by §281.8(b)(2) of this title (relating to Grounds for Discipline for a Pharmacy License): up to $1,000;
(Y) failing to keep, maintain or furnish an annual inventory as required by §291.17 of this title (relating to Inventory Requirements): $1,000;
(Z) failing to obtain training on the preparation of sterile pharmaceutical compounding: $1,500;
(AA) failing to maintain the confidentiality of prescription records: $1,000 - $5,000;
(BB) failing to inform the board of any notification or information required to be reported by the Act or rules: $250 - $500; [and]
(CC) failing to operate a pharmacy as specified in [provided by] §291.11 of this title (relating to Operation of a Pharmacy): $3,000; and[.]
(DD) operating a Class E or Class E-S pharmacy without a Texas licensed pharmacist-in-charge: $1,000 - $5,000.
(3) The following violations by a pharmacy technician may be appropriate for disposition with an administrative penalty with or without additional sanctions or restrictions:
(A) - (K) (No change.)
(L) accessing information submitted to the Prescription Monitoring Program in violation of §481.076 of the Controlled Substances Act: $1,000 - $5,000.
(4) - (6) (No change.)
TRD-201700766
22 TAC §291.3
The Texas State Board of Pharmacy proposes amendments to §291.3, concerning Required Notifications. The amendments to §291.3, if adopted, update the requirements for a change of name for a pharmacy; update the notification requirements for internet sites verified by NABP; add a requirement for pharmacies and pharmacists to report disciplinary action by another state to TSBP as required by §562.106 of the Act; and clarify requirements to be consistent with other sections of the rules.
Written comments on the amendments may be submitted to Allison Vordenbaumen Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas 78701, FAX (512) 305-6778. Comments must be received by 5 p.m., April 14, 2017.
The amendments are proposed under §§551.002 and 554.051 of the Texas Pharmacy Act (Chapters 551 - 569, Texas Occupations Code). The Board interprets §551.002 as authorizing the agency to protect the public through the effective control and regulation of the practice of pharmacy. The Board interprets §554.051(a) as authorizing the agency to adopt rules for the proper administration and enforcement of the Act.
§291.3.Required Notifications.
(a) Change of Location [and/or Name].
(1) When a pharmacy changes location [and/or name], the following is applicable.
(A) A new completed pharmacy application containing the information outlined in §291.1 of this title (relating to Pharmacy License Application), must be filed with the board not later than 30 days before the date of the change of location of the pharmacy.
(B) The previously issued license must be returned to the board office.
(C) An amended license reflecting the new location [and/or name] of the pharmacy will be issued by the board; and
(D) A fee as specified in §291.6 of this title (relating to Pharmacy License Fees) will be charged for issuance of the amended license.
(2) At least 14 days prior to the change of location of a pharmacy that dispenses prescription drug orders, the pharmacist-in-charge shall post a sign in a conspicuous place indicating that the pharmacy is changing locations. Such sign shall be in the front of the prescription department and at all public entrance doors to the pharmacy and shall indicate the date the pharmacy is changing locations.
(3) Disasters, accidents, and emergencies which require the pharmacy to change location shall be immediately reported to the board. If a pharmacy changes location suddenly due to disasters, accidents, or other emergency circumstances and the pharmacist-in-charge cannot provide notification 14 days prior to the change of location, the pharmacist-in-charge shall comply with the provisions of paragraph (2) of this subsection as far in advance of the change of location as allowed by the circumstances.
(b) Change of Name. When a pharmacy changes its name, the following is applicable.
(1) A new completed pharmacy application containing the information outlined in §291.1 of this title (relating to Pharmacy License Application), must be filed with the board within 10 days of the change of name of the pharmacy.
(2) The previously issued license must be returned to the board office.
(3) An amended license reflecting the new name of the pharmacy will be issued by the board; and
(4) A fee as specified in §291.6 of this title (relating to Pharmacy License Fees) will be charged for issuance of the amended license.
(c) [(b)] Change of Managing Officers.
(1) The owner of a pharmacy shall notify the board in writing within 10 days of a change of any managing officer of a partnership or corporation which owns a pharmacy. The written notification shall include the effective date of such change and the following information for all managing officers:
(A) name and title;
(B) home address and telephone number;
(D) a copy of social security card or other official document showing the social security number as approved by the board; [however, if an individual is unable to obtain a social security number, an individual taxpayer identification number may be provided in lieu of a social security number along with documentation indicating why the individual is unable to obtain a social security number;] and
(E) a copy of current driver's license, state issued photo identification card, or passport.
(2) For purposes of this subsection, managing officers are defined as the top four executive officers, including the corporate officer in charge of pharmacy operations, who are designated by the partnership or corporation to be jointly responsible for the legal operation of the pharmacy.
(d) [(c)] Change of Ownership.
(1) When a pharmacy changes ownership, a new pharmacy application must be filed with the board following the procedures as specified in §291.1 of this title (relating to Pharmacy License Application). In addition, a copy of the purchase contract or mutual agreement between the buyer and seller must be submitted.
(2) The license issued to the previous owner must be returned to the board.
(3) A fee as specified in §291.6 of this title will be charged for issuance of a new license.
(e) [(d)] Change of Pharmacist Employment.
(1) Change of pharmacist employed in a pharmacy. When a change in pharmacist employment occurs, the pharmacist shall report such change in writing to the board within 10 days.
(2) Change of pharmacist-in-charge of a pharmacy. The incoming pharmacist-in-charge shall be responsible for notifying the board within 10 days in writing on a form provided by the board that a change of pharmacist-in-charge has occurred. The notification shall include the following:
(A) the name and license number of the departing pharmacist-in-charge;
(B) the name and license number of the incoming pharmacist-in-charge;
(C) the date the incoming pharmacist-in-charge became the pharmacist-in-charge; and
(D) a statement signed by the incoming pharmacist-in-charge attesting that:
(i) an inventory, as specified in §291.17 of this title (relating to Inventory Requirements), has been conducted by the departing and incoming pharmacists-in-charge; if the inventory was not taken by both pharmacists, the statement shall provide an explanation; and
(ii) the incoming pharmacist-in-charge has read and understands the laws and rules relating to this class of pharmacy.
(f) [(e)] Notification of Theft or Loss of a Controlled Substance or a Dangerous Drug.
(1) Controlled substances. For the purposes of the Act, §562.106, the theft or significant loss of any controlled substance by a pharmacy shall be reported in writing to the board immediately on discovery of such theft or loss. A pharmacy shall be in compliance with this subsection by submitting to the board a copy of the Drug Enforcement Administration (DEA) report of theft or loss of controlled substances, DEA Form 106, or by submitting a list of all controlled substances stolen or lost.
(2) Dangerous drugs. A pharmacy shall report in writing to the board immediately on discovery the theft or significant loss of any dangerous drug by submitting a list of the name and quantity of all dangerous drugs stolen or lost.
(g) [(f)] Fire or Other Disaster. If a pharmacy experiences a fire or other disaster, the following requirements are applicable.
(1) Responsibilities of the pharmacist-in-charge.
(A) The pharmacist-in-charge shall be responsible for reporting the date of the fire or other disaster which may affect the strength, purity, or labeling of drugs, medications, devices, or other materials used in the diagnosis or the treatment of the injury, illness, and disease; such notification shall be immediately reported to the board, but in no event shall exceed 10 days from the date of the disaster.
(B) The pharmacist-in-charge or designated agent shall comply with the following procedures.
(i) If controlled substances, dangerous drugs, or Drug Enforcement Administration (DEA) order forms are lost or destroyed in the disaster, the pharmacy shall:
(I) notify the DEA[, Department of Public Safety (DPS),] and the board [Texas State Board of Pharmacy (board)] of the loss of the controlled substances or order forms. A pharmacy shall be in compliance with this section by submitting to each of these agencies a copy of the DEA's report of theft or loss of controlled substances, DEA Form-106, immediately on discovery of the loss; and
(II) notify the board in writing of the loss of the dangerous drugs by submitting a list of the dangerous drugs lost.
(ii) If the extent of the loss of controlled substances or dangerous drugs is not able to be determined, the pharmacy shall:
(I) take a new, complete inventory of all remaining drugs specified in §291.17(c) of this title (relating to Inventory Requirements);
(II) submit to DEA [and DPS] a statement attesting that the loss of controlled substances is indeterminable and that a new, complete inventory of all remaining controlled substances was conducted and state the date of such inventory; and
(III) submit to the board a statement attesting that the loss of controlled substances and dangerous drugs is indeterminable and that a new, complete inventory of the drugs specified in §291.17(c) of this title was conducted and state the date of such inventory.
(C) If the pharmacy changes to a new, permanent location, the pharmacist-in-charge shall comply with subsection (a) of this section.
(D) If the pharmacy moves to a temporary location, the pharmacist shall comply with subsection (a) of this section. If the pharmacy returns to the original location, the pharmacist-in-charge shall again comply with subsection (a) of this section.
(E) If the pharmacy closes due to fire or other disaster, the pharmacy may not be closed for longer than 90 days as specified in §291.11 of this title (relating to Operation of a Pharmacy).
(F) If the pharmacy discontinues business (ceases to operate as a pharmacy), the pharmacist-in-charge shall comply with §291.5 of this title (relating to Closing a Pharmacy).
(G) The pharmacist-in-charge shall maintain copies of all inventories, reports, or notifications required by this section for a period of two years.
(2) Drug stock.
(A) Any drug which has been exposed to excessive heat, smoke, or other conditions which may have caused deterioration shall not be dispensed.
(B) Any potentially adulterated or damaged drug shall only be sold, transferred, or otherwise distributed pursuant to the provisions of the Texas Food Drug and Cosmetics Act (Chapter 431, Health and Safety Code) administered by the Bureau of Food and Drug Safety of the Texas Department of State Health Services.
(h) [(g)] Notification to Consumers.
(1) Pharmacy.
(A) Every licensed pharmacy shall provide notification to consumers of the name, mailing address, Internet site address, and telephone number of the board for the purpose of directing complaints concerning the practice of pharmacy to the board. Such notification shall be provided as follows.
(i) If the pharmacy serves walk-in customers, the pharmacy shall either:
(I) post in a prominent place that is in clear public view where prescription drugs are dispensed:
(-a-) a sign which notifies the consumer that complaints concerning the practice of pharmacy may be filed with the board and list the board's name, mailing address, Internet site address, telephone number, and a toll-free telephone number for filing complaints; or
(-b-) an electronic messaging system in a type size no smaller than ten-point Times Roman which notifies the consumer that complaints concerning the practice of pharmacy may be filed with the board and list the board's name, mailing address, Internet site address, telephone number, and a toll-free number for filing complaints; or
(II) provide with each dispensed prescription a written notification in a type size no smaller than ten-point Times Roman which states the following: "Complaints concerning the practice of pharmacy may be filed with the Texas State Board of Pharmacy at: (list the mailing address, Internet site address, telephone number of the board, and a toll-free telephone number for filing complaints)."
(ii) If the prescription drug order is delivered to patients at their residence or other designated location, the pharmacy shall provide with each dispensed prescription a written notification in type size no smaller than ten-point Times Roman which states the following: "Complaints concerning the practice of pharmacy may be filed with the Texas State Board of Pharmacy at: (list the mailing address, Internet site address, telephone number, and a toll-free telephone number for filing complaints)." If multiple prescriptions are delivered to the same location, only one such notice shall be required.
(iii) The provisions of this subsection do not apply to prescriptions for patients in facilities where drugs are administered to patients by a person required to do so by the laws of the state (i.e., nursing homes).
(B) A pharmacy that maintains a generally accessible site on the Internet that is located in Texas or sells or distributes drugs through this site to residents of this state shall post the following information on the pharmacy's initial home page and on the page where a sale of prescription drugs occurs.
(i) Information on the ownership of the pharmacy, to include at a minimum, the:
(I) owner's name or if the owner is a partnership or corporation, the partnership's or corporation's name and the name of the chief operating officer;
(II) owner's address;
(III) owner's telephone number; and
(IV) year the owner began operating pharmacies in the United States.
(ii) The Internet address and toll free telephone number that a consumer may use to:
(I) report medication/device problems to the pharmacy; and
(II) report business compliance problems.
(iii) Information about each pharmacy that dispenses prescriptions for this site, to include at a minimum, the:
(I) pharmacy's name, address, and telephone number;
(II) name of the pharmacist responsible for operation of the pharmacy;
(III) Texas pharmacy license number for the pharmacy and a link to the Internet site maintained by the Texas State Board of Pharmacy; and
(IV) the names of all other states in which the pharmacy is licensed, the license number in that state, and a link to the Internet site of the entity that regulates pharmacies in that state, if available.
(C) A pharmacy whose Internet site has been verified [awarded a Verified Internet Pharmacy Practice Sites (VIPPS), Veterinary-Verified Internet Pharmacy Practice Sites (Vet-VIPPS) accreditation, or e-Advertiser Approval Program] by the National Association of Boards of Pharmacy to be in compliance with the laws of this state, as well as in all other states in which the pharmacy is licensed shall be in compliance with subparagraph (B) of this paragraph [by displaying the VIPPS, Vet-VIPPS, or e-Advertiser seal on the pharmacy internet site].
(2) Texas State Board of Pharmacy. On or before January 1, 2005, the board shall establish a pharmacy profile system as specified in §2054.2606, Government Code.
(A) The board shall make the pharmacy profiles available to the public on the agency's Internet site.
(B) A pharmacy profile shall contain at least the following information:
(i) name, address, and telephone number of the pharmacy;
(ii) pharmacy license number, licensure status, and expiration date of the license;
(iii) the class and type of the pharmacy;
(iv) ownership information for the pharmacy;
(v) names and license numbers of all pharmacists working at the pharmacy;
(vi) whether the pharmacy has had prior disciplinary action by the board;
(vii) whether the pharmacy's consumer service areas are accessible to disabled persons, as defined by law;
(viii) the type of language translating services, including translating services for persons with impairment of hearing, that the pharmacy provides for consumers; and
(ix) insurance information including whether the pharmacy participates in the state Medicaid program.
(C) The board shall gather this information on initial licensing and update the information in conjunction with the license renewal for the pharmacy.
(i) [(h)] Notification of Licensees or Registrants Obtaining Controlled Substances or Dangerous Drugs by Forged Prescriptions. If a licensee or registrant obtains controlled substances or dangerous drugs from a pharmacy by means of a forged prescription, the pharmacy shall report in writing to the board immediately on discovery of such forgery. A pharmacy shall be in compliance with this subsection by submitting to the board the following:
(1) name of licensee or registrant obtaining controlled substances or dangerous drugs by forged prescription;
(2) date(s) of forged prescription(s);
(3) name(s) and amount(s) of drug(s); and
(4) copies of forged prescriptions.
(j) Notification of Disciplinary Action. For the purpose of the Act, §562.106, a pharmacy shall report in writing to the board not later than the 10th day after the date of:
(1) a final order against the pharmacy license holder by the regulatory or licensing agency of the state in which the pharmacy is located if the pharmacy is located in another state; or
(2) a final order against a pharmacist who is designated as the pharmacist-in-charge of the pharmacy by the regulatory or licensing agency of the state in which the pharmacy is located if the pharmacy is located in another state.
TRD-201700763
Gay Dodson, R. Ph.
SUBCHAPTER C. NUCLEAR PHARMACY (CLASS B)
22 TAC §291.52
The Texas State Board of Pharmacy proposes amendments to §291.52, concerning Definitions. The amendments, if adopted, add the definition of a full-time pharmacist to the Nuclear (Class B) pharmacy rules.
Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the amendments will ensure nuclear pharmacies are properly supervised by the pharmacist-in-charge. There is no fiscal impact for individuals, small or large businesses, or to other entities which are required to comply with this section.
Written comments on the amendments may be submitted to Allison Vordenbaumen Benz, R.Ph., M.S., Director of Professional Services, Texas State Board of Pharmacy, 333 Guadalupe Street, Suite 3-600, Austin, Texas 78701, FAX (512) 305-6778. Comments must be received by 5:00 p.m., April 14, 2017.
§291.52.Definitions.
The following words and terms, when used in this subchapter, shall have the following meanings, unless the context clearly indicates otherwise. Any term not defined in this section shall have the definition set forth in the Act, §551.003.
(1) Act--The Texas Pharmacy Act, Chapters 551 - 569, Occupations Code, as amended.
(2) Accurately as prescribed--Dispensing, delivering, and/or distributing a prescription drug order or radioactive prescription drug order:
(A) to the correct patient (or agent of the patient) for whom the drug or device was prescribed;
(B) with the correct drug in the correct strength, quantity, and dosage form ordered by the practitioner; and
(C) with correct labeling (including directions for use) as ordered by the practitioner. Provided, however, that nothing herein shall prohibit pharmacist substitution if substitution is conducted in strict accordance with applicable laws and rules, including Subchapter A, Chapter 562 of the Act.
(3) ACPE--Accreditation Council for Pharmacy Education.
(4) Administer--The direct application of a prescription drug and/or radiopharmaceutical, by injection, inhalation, ingestion, or any other means to the body of a patient by:
(A) a practitioner, an authorized agent under his supervision, or other person authorized by law; or
(B) the patient at the direction of a practitioner.
(5) Authentication of product history--Identifying the purchasing source, the intermediate handling, and the ultimate disposition of any component of a radioactive drug.
(6) Authorized nuclear pharmacist--A pharmacist who:
(A) has completed the specialized training requirements specified by this subchapter for the preparation and distribution of radiopharmaceuticals; and
(B) is named on a Texas radioactive material license, issued by the Texas Department of State Health Services, Radiation Control Program.
(7) Authorized user--Any individual named on a Texas radioactive material license, issued by the Texas Department of State Health Services, Radiation Control Program.
(8) Board--The Texas State Board of Pharmacy.
(9) Component--Any ingredient intended for use in the compounding of a drug preparation, including those that may not appear in such preparation.
(10) Compounding--The preparation, mixing, assembling, packaging, or labeling of a drug or device:
(A) as the result of a practitioner's prescription drug or medication order based on the practitioner-patient-pharmacist relationship in the course of professional practice;
(B) for administration to a patient by a practitioner as the result of a practitioner's initiative based on the practitioner-patient-pharmacist relationship in the course of professional practice;
(C) in anticipation of prescription drug or medication orders based on routine, regularly observed prescribing patterns; or
(D) for or as an incident to research, teaching, or chemical analysis and not for sale or dispensing, except as allowed under §562.154 or Chapter 563 of the Act.
(11) Controlled substance--A drug, immediate precursor, or other substance listed in Schedules I - V or Penalty Groups 1-4 of the Texas Controlled Substances Act, as amended, or a drug, immediate precursor, or other substance included in Schedule I, II, III, IV, or V of the Federal Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended (Public Law 91-513).
(12) Dangerous drug--A drug or device that:
(A) is not included in Penalty Group 1, 2, 3, or 4, Chapter 481, Health and Safety Code, and is unsafe for self-medication; or
(B) bears or is required to bear the legend:
(i) "Caution: federal law prohibits dispensing without prescription" or "Rx only" or another legend that complies with federal law; or
(ii) "Caution: federal law restricts this drug to use by or on the order of a licensed veterinarian."
(13) Data communication device--An electronic device that receives electronic information from one source and transmits or routes it to another (e.g., bridge, router, switch, or gateway).
(14) Deliver or delivery--The actual, constructive, or attempted transfer of a prescription drug or device, radiopharmaceutical, or controlled substance from one person to another, whether or not for a consideration.
(15) Designated agent--
(A) an individual, including a licensed nurse, physician assistant, nuclear medicine technologist, or pharmacist:
(i) who is designated by a practitioner and authorized to communicate a prescription drug order to a pharmacist; and
(ii) for whom the practitioner assumes legal responsibility;
(B) a licensed nurse, physician assistant, or pharmacist employed in a health care facility to whom a practitioner communicates a prescription drug order; or
(C) a registered nurse or physician assistant authorized by a practitioner to administer a prescription drug order for a dangerous drug under Subchapter B, Chapter 157 (Occupations Code).
(16) Device--An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related articles, including any component parts or accessory that is required under federal or state law to be ordered or prescribed by a practitioner.
(17) Diagnostic prescription drug order--A radioactive prescription drug order issued for a diagnostic purpose.
(18) Dispense--Preparing, packaging, compounding, or labeling for delivery a prescription drug or device, or a radiopharmaceutical in the course of professional practice to an ultimate user or his agent by or pursuant to the lawful order of a practitioner.
(19) Dispensing pharmacist--The authorized nuclear pharmacist responsible for the final check of the dispensed prescription before delivery to the patient.
(20) Distribute--The delivering of a prescription drug or device, or a radiopharmaceutical other than by administering or dispensing.
(21) Electronic radioactive prescription drug order--A radioactive prescription drug order which is transmitted by an electronic device to the receiver (pharmacy).
(22) Full-time pharmacist--A pharmacist who works in a pharmacy at least 30 hours per week or, if the pharmacy is open less than 60 hours per week, one-half of the time the pharmacy is open.
(23) [(22)] Hot water--The temperature of water from the pharmacy's sink maintained at a minimum of 105 degrees F (41 degrees C).
(24) [(23)] Nuclear pharmacy technique--The mechanical ability required to perform the nonjudgmental, technical aspects of preparing and dispensing radiopharmaceuticals.
(25) [(24)] Original prescription--The:
(A) original written radioactive prescription drug orders; or
(B) original verbal or electronic radioactive prescription drug orders maintained either manually or electronically by the pharmacist.
(26) [(25)] Pharmacist-in-charge--The pharmacist designated on a pharmacy license as the pharmacist who has the authority or responsibility for a pharmacy's compliance with laws and rules pertaining to the practice of pharmacy.
(27) [(26)] Pharmacy technician--An individual whose responsibility in a pharmacy is to provide technical services that do not require professional judgment regarding preparing and distributing drugs and who works under the direct supervision of and is responsible to a pharmacist.
(28) [(27)] Pharmacy technician trainee--An individual who is registered with the board as a pharmacy technician trainee and is authorized to participate in a pharmacy's technician training program.
(29) [(28)] Radiopharmaceutical--A prescription drug or device that exhibits spontaneous disintegration of unstable nuclei with the emission of a nuclear particle(s) or photon(s), including any nonradioactive reagent kit or nuclide generator that is intended to be used in preparation of any such substance.
(30) [(29)] Radioactive drug service--The act of distributing radiopharmaceuticals; the participation in radiopharmaceutical selection and the performance of radiopharmaceutical drug reviews.
(31) [(30)] Radioactive prescription drug order--An order from a practitioner or a practitioner's designated agent for a radiopharmaceutical to be dispensed.
(32) [(31)] Sterile radiopharmaceutical--A dosage form of a radiopharmaceutical free from living micro-organisms.
(33) [(32)] Therapeutic prescription drug order--A radioactive prescription drug order issued for a specific patient for a therapeutic purpose.
(34) [(33)] Ultimate user--A person who has obtained and possesses a prescription drug or radiopharmaceutical for administration to a patient by a practitioner.
TRD-201700764
CHAPTER 315. CONTROLLED SUBSTANCES
22 TAC §315.3
The Texas State Board of Pharmacy proposes amendments to §315.3 concerning Definitions. The amendments, if adopted, clarify the requirements for dispensing schedule II prescriptions when issued as a multiple set.
Ms. Dodson has determined that, for each year of the first five-year period the rule will be in effect, the public benefit anticipated as a result of enforcing the amendments will ensure pharmacies are dispensing schedule II medications within the authorized timeframes. There is no fiscal impact for individuals, small or large businesses, or to other entities which are required to comply with this section.
§315.3.Prescriptions - Effective September 1, 2016.
(a) Schedule II Prescriptions.
(1) Except as provided by subsection (e) of this section, a practitioner, as defined in the TCSA, §481.002(39)(A), must issue a written prescription for a Schedule II controlled substance only on an official Texas prescription form or through an electronic prescription that meets all requirements of the TCSA. This subsection also applies to a prescription issued in an emergency situation.
(2) A practitioner who issues a written prescription for any quantity of a Schedule II controlled substance must complete an official prescription form [by legibly completing the spaces provided].
(3) A practitioner may issue multiple written prescriptions authorizing a patient to receive up to a 90-day supply of a Schedule II controlled substance provided:
(A) each prescription is issued for a legitimate medical purpose by a [while] practitioner [is] acting in the usual course of professional practice;
(B) the practitioner provides written instructions on each prescription, other than the first prescription if the practitioner intends for that prescription to be filled immediately, [that is to be dispensed within 21 days of issuance,] indicating the earliest date on which a pharmacy may dispense each prescription; and
(C) the practitioner concludes that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse.
(4) A schedule II prescription must be dispensed within 21 days of issuance or, if the prescription is part of a multiple set of prescriptions, within 21 days of the earliest date on which a pharmacy may dispense the prescription.
(b) Schedules III through V Prescriptions.
(1) A practitioner, as defined in the TCSA, §481.002(39)(A), (C), (D), may use prescription forms and order forms through individual sources. A practitioner may issue, or allow to be issued by a person under the practitioner's direction or supervision, a Schedule III through V controlled substance on a prescription form for a valid medical purpose and in the course of medical practice.
(2) Schedule III through V prescriptions may be refilled up to five times within six months after date of issuance.
(c) Electronic prescription. A practitioner is permitted to issue and to dispense an electronic controlled substance prescription only in accordance with the requirements of the Code of Federal Regulations, Title 21, Part 1311.
(d) Controlled Substance prescriptions may not be postdated.
(e) Advanced practice registered nurses or physician assistants may only use the official prescription forms issued with their name, address, phone number, and DEA numbers, and the delegating physician's name and DEA number. [The official prescription order form must be signed by the requesting advanced practice registered nurse or physician assistant, and by the delegating physician.]
TRD-201700765